Posted by Michael Wonder on 07 Oct 2025
Enhertu plus pertuzumab supplemental new drug application submitted in Japan as first-line therapy for patients with HER2 positive metastatic breast cancer
7 October 2025 - Submission based on DESTINY-Breast09 Phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus a taxane, trastuzumab and pertuzumab with a median progression-free survival of greater than three years.
Daiichi Sankyo has submitted a supplemental new drug application to Japan’s MHLW for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the treatment of patients with HER2 positive unresectable or recurrent breast cancer.
